MHC-II Detection for Immunotherapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy methods for cancer are costly and not effective for all patients, with limited accuracy in predicting response due to technical difficulties and low accuracy of PD-L1 staining protocols.
Innovation Solution
A method involving the detection of cell membrane expression of MHC molecules, such as HLA-DR, in tumor cells using antibodies and techniques like immunohistochemistry or flow cytometry to predict the effectiveness of immunotherapy, allowing for the administration of targeted immunotherapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PD-L1 staining is used to predict immunotherapy response, then treatment guidance is provided, but accuracy is limited (62% accuracy) and technical difficulties arise requiring frozen tissue
Solution Approach 1:
The patent changes the measured parameter from PD-L1 expression to MHC-II molecule expression (specifically HLA-DR). This parameter change enables accurate prediction of immunotherapy response using standard formalin-fixed tissue processing, eliminating the technical difficulties associated with frozen tissue requirements while maintaining or improving predictive accuracy
Solution Approach 2:
The patent employs standard formalin-fixed tissue processing which is widely available, stable, and does not require specialized frozen tissue facilities. This makes the testing method more accessible and eliminates the need for complex cryopreservation infrastructure
2Productivity
If immunotherapy is administered to all cancer patients, then treatment coverage is maximized, but cost and toxicity increase without benefit for non-responders
Solution Approach 1:
The patent performs MHC-II expression testing before immunotherapy administration to identify patients likely to respond. This preliminary action enables selective treatment of responsive patients, avoiding unnecessary treatment of non-responders and thereby reducing resource waste while maintaining appropriate treatment coverage
Solution Approach 2:
The patent uses MHC-II expression levels as a biomarker to provide feedback on predicted treatment response. This feedback mechanism guides treatment decisions, allowing clinicians to tailor immunotherapy administration to patients most likely to benefit, optimizing the balance between treatment coverage and resource utilization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the accuracy of predicting patient response to immunotherapy, enabling more effective treatment by identifying patients likely to benefit from specific immunotherapies, such as anti-PD-1/PD-L1 therapies, and potentially enhancing treatment outcomes.
Implementation Method 1
detecting cell membrane expression of the MHC molecule by contacting the tumor cell sample with an antibody targeting the MHC molecule and detecting binding between the MHC molecule and the antibody
Data Source
AI summary
A method of detecting cell membrane expression of an MHC molecule in a subject, a method of treating cancer in a subject with an immunotherapeutic agent, and an MHC complex are provided. The method of detecting cell membrane expression of an MHC molecule includes obtaining a tumor cell sample from a subject, and detecting cell membrane expression of the MHC molecule by contacting the tumor cell sample with an antibody targeting the MHC molecule and detecting binding between the MHC molecule and the antibody. The method of treating cancer in a subject with an immunotherapeutic agent includes detecting cell membrane expression of an MHC molecule in the subject and administering a therapeutically effective amount of the immunotherapeutic agent if the level of cell membrane expression of the MHC molecule exceeds a predetermined standard. The complex includes a tumor cell in complex with an antibody or an antigen-binding portion thereof.